Skip to content
akaturk Academic measurement

Article detail · 2024

Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells

Journal

Pamukkale Medical Journal

ISSN 1309-9833

YÖKSİS OpenAlex Open access · hybrid SJR Q4 TR Index Citations 1 Percentile 53.6% FWCI 0.29
Year
2024
Type
article

Data source split

  • YÖKSİS YÖKSİS article record
  • YÖKSİS venue Pamukkale Medical Journal
  • Catalog match (ISSN) Pamukkale Medical Journal
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

Abstract

OpenAlex · English

Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

1 citations

OpenAlex cited_by_count (cache / database)

Authors

  1. YAVUZ DODURGA
  2. LEVENT ELMAS
  3. MÜCAHİT SEÇME
  4. Nazlı Demirkıran
  5. ÇIĞIR BİRAY AVCI EGE ÜNİVERSİTESİ
  6. GÜLSEREN BAĞCI
  7. Sevda Sağ
  8. Lale Şatıroğlu Tufan